Clinical Trial Update: Brentuximab Vedotin in CD30 Positive Epstein Barr Virus (EBV) Positive DLBCL of Elderly [NA]

View source ↗

Summary

A clinical trial evaluating Brentuximab vedotin for CD30-positive EBV-positive diffuse large B-cell lymphoma in elderly patients has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Ebv-positive Diffuse Large B-cell Lymphoma

Drugs mentioned

• Adcetris (Brentuximab vedotin)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Lymphoma | NA | Status: WITHDRAWN